Episode#36 March 27th 2026: Merck's $20M Quotient Bet

Episode#39 Apr 1st 2026: Lilly's Centessa Bet

* Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play * Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinic * Merck enlists antibody hunter Infinimmune for $838M biobucks pact

Episode#38 Mar 31st 2026: Basecamp's Trillion-Gene Atlas

* Mapping the Trillion-Gene Universe: The Startup That Wants to Teach AI the Language of Life * Why Data Infrastructure Determines AI Success in Drug Discovery * PhenoTips, Health Institutions Launch C$5.4M AI Genomic Medicine Initiative in Canada

Episode#37 Mar 30th 2026: AstraZeneca's IL‑33 Win

AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B Merck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals

Episode#36 March 27th 2026: Merck's $20M Quotient Bet

* The Value of Prediction, and Cost of Success, in Drug Hunting * Merck hands over $20M in IBD drug target deal with Flagship's Quotient * The N-of-1 Revolution in Personalized Medicine

Episode#35 Mar 26th 2026: Merck's Terns Play

- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition - OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline - Sarepta's big bet on Arrowhead's siRNA assets yields early data